Dealmaking

Inflation fears ramp up, Ares agrees to acquire The Lockwood Group, Softbank leads $122m funding round in DICE

Inflation worries are getting worse, as ships remain jammed up in the Port of Los Angeles and Europe and the UK are bracing for an energy crisis as there’s not enough fuel to meet demand.

Ares to buy The Lockwood Group at mid-$300m value

Houlihan Lokey advises the Stamford, Connecticut-based medical communications business on its pending sale.

Clearlake runs secondaries deal for Symplr, TPG names Todd Sisitsky president

If any healthcare readers out there are heading to the Healthcare Innovation and Investment conference in Chicago next week, hit me up, I'll be there!

Friday Letter: The seed explosion creates frenemies

Greylock's largest pool of capital for seed deals comes as more mega-funds are pouring into the seed-stage. The question is: how will this impact the pure seed-stage investor?

Clearlake runs process for more time, capital for healthcare tech company Symplr

The single-asset deal is in a market that has been flooded with GP-led transactions as managers look for ways to hold treasured assets beyond the parameters of traditional private equity funds.

Big VC names matter little when recruiting tech talent

New talent wants to work somewhere with a mission, according to Contrary Capital.

NYC Comptroller names head of private equity, GA-backed Alternative Health Solutions considers strategic deals

NYC comptroller Scott Stringer announced that senior investment officer Eneasz Kadziela was promoted to lead private equity for the entire city system.

GA’s Alternate Solutions Health Network explores options following strategic interest

Harris Williams is providing financial advice to the company, which partners with not-for-profit health systems to manage the discharge of patients.

Bench of healthcare services buyers widens as investors chase growth, Platinum Equity's PCI goes to Celestica for $306m

Yesterday, we saw Great Hill Partners announce its first pure-play healthcare services deal.

Technology adoption reluctance in PE: demystifying the top five objections

Enlightened funds no longer see tech as a luxury, but rather as mission critical to attracting investment, winning deals, extracting maximum portfolio value and delivering results.